Takeda to collaborate with JCR Pharma to commercialise next-gen Hunter Syndrome therapy
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
The American Association for Clinical Chemistry (AACC); the American Society for Clinical Pathology (ASCP); the American Society of Hematology (ASH); and the International Myeloma Working Group (IMWG), collaborate to develop the guideline
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Subscribe To Our Newsletter & Stay Updated